A phase 11 study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma
- Authors
- Seo, JH; Whang, YM; Kim, BS; Choi, CW; Shin, SW; Kim, YH; Kim, JS; Goo, BH
- Issue Date
- 1-4월-2002
- Publisher
- JOHN WILEY & SONS INC
- Keywords
- anthracycline resistance; breast carcinoma; paclitaxel; ifosfamide
- Citation
- CANCER, v.94, no.7, pp.1925 - 1930
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER
- Volume
- 94
- Number
- 7
- Start Page
- 1925
- End Page
- 1930
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/124385
- DOI
- 10.1002/cncr.10431
- ISSN
- 0008-543X
- Abstract
- BACKGROUND. A Phase 11 study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). METHODS. Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m(2)) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m(2)/day) with mesna (360 mg/m(2)/day) on Days 2- 4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS. Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemo therapy-related death. CONCLUSIONS. Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.